Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis - Takeaways - MDSpire

Magmaris bioresorbable magnesium scaffold in acute coronary syndromes: a systematic review and meta-analysis

  • By

  • Simon Wölbert

  • Pablo F. F. Escrihuela-Branz

  • Stephanie Gladys Kühne

  • Andrea Patrignani

  • Mauro Chiarito

  • Jan Torzewski

  • Philip W. J. Raake

  • Dario Bongiovanni

  • May 20, 2026

  • 0 min

Share

  • 1

    The Magmaris bioresorbable magnesium scaffold was evaluated for safety and efficacy in acute coronary syndromes compared to drug-eluting stents.

  • 2

    No significant difference in target-lesion failure rates was found between Magmaris and drug-eluting stents at one year.

  • 3

    Target-lesion revascularization rates were significantly higher with Magmaris compared to drug-eluting stents.

  • 4

    Magmaris demonstrated low scaffold thrombosis rates, but its comparative safety and efficacy remain uncertain due to limited evidence.

  • 5

    Further technical improvements in magnesium scaffolds are necessary before considering Magmaris a robust alternative in acute coronary syndromes.

Original Source(s)

Related Content